Objective
The overall objective of the viRgil Network of Excellence is to set up the first-ever European Vigilance Network capable of addressing current and emerging antiviral drugs resistance developments. Focusing first on three major diseases (influenza and viral hepatitis B and C), our strategy is to build a sustainable, patient-oriented 'virtual institute' by integrating the currently fragmented European capacities into interacting platforms that together will allow the containment of the problem of viral drug resistance. Being approach- rather than virus- based, the integration process will be flexible enough to embrace in the future drug resistance problems related to other human viruses. Indeed, the proposed complementary platforms will focus each on a topic contributing towards broad objectives: the setting-up of the viRgil clinical platforms (surveillance and virology) will allow a global approach for monitoring, testing and ultimately improving the management of antiviral drug resistance in treated patients, leading to outstanding practices and standards in Europe. Attention will be paid to specific patient communities (children, women). These activities will be strengthened by knowledge generated from the in vitro and in vivo models platform, which will elucidate the mechanisms of the the development of resistance, and from the host determinants platform aiming at understanding patient-related (immune/genetic) factors conditioning viral drug resistance. Platforms dedicated to drugs and pharmacological aspects as well as innovation and technology will enable to anticipate viral resistance against promising drugs closed to clinical application and to overcome future resistance problems by proposing more rational approaches for drug development to the private sector and effective tools for testing resistance to the clinicians. Lastly, viRgil objectives and the benefit for the community will be constantly evaluated by the societal impact platforrm.
Fields of science
- medical and health scienceshealth sciencesinfectious diseasesDNA viruseshepatitis B
- medical and health scienceshealth sciencesinfectious diseasesRNA viruseshepatitis C
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenza
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantivirals
Topic(s)
Call for proposal
FP6-2002-LIFESCIHEALTH
See other projects for this call
Funding Scheme
NoE - Network of ExcellenceCoordinator
PARIS
France
See on map
Participants (57)
VILLEURBANNE
See on map
HANNOVER
See on map
CRÉTEIL
See on map
LONDON
See on map
HEIDELBERG
See on map
LONDON
See on map
MUNICH
See on map
DÜSSELDORF
See on map
LEUVEN
See on map
9600 LEIDEN
See on map
LONDON
See on map
F-75018 PARIS
See on map
ROTTERDAM
See on map
PADOVA
See on map
BARCELONA
See on map
BARCELONA
See on map
THESSALONIKI
See on map
BIRMINGHAM
See on map
3006 GENÈVE 4
See on map
LOUVAIN-LA-NEUVE
See on map
MADRID
See on map
LONDON
See on map
15 11 50 SAARBRÜCKEN
See on map
ROME
See on map
PARIS
See on map
TUEBINGEN
See on map
MARBURG
See on map
MADRID
See on map
BP 53 GRENOBLE
See on map
FREIBURG
See on map
256 UPPSALA
See on map
MILAN
See on map
HAMBURG
See on map
PARIS
See on map
OXFORD
See on map
GIESSEN
See on map
BERLIN
See on map
BERLIN
See on map
STOCKHOLM
See on map
LONDON
See on map
BARI
See on map
BERN
See on map
INNSBRUCK
See on map
PARIS
See on map
MARCY-L'ETOILE
See on map
RAMAT-GAN
See on map
CAMBRIDGE
See on map
1568 UTRECHT
See on map
ROME
See on map
MUENSTER
See on map
11500 THE HAGUE
See on map
LONDON
See on map
2021 LUXEMBOURG
See on map
AACHEN
See on map
GIESSEN
See on map
GDANSK
See on map
PARIS
See on map